# A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07623356/  
OnCo record `nct07623356` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ivonescimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.

## Summary

A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07623356 by Akeso, with 265 participants planned, started 2026-07-07 and due to reach its primary completion in 2028-06-18. Interventions recorded: AK138D1, Ivonescimab, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07623356
- Phase: 1/2
- Setting: A Phase Ib/II Study of AK138D1 as Monotherapy and in Combination With Ivonescimab in Patients With Advanced Non-Small Cell Lung Cancer
- Sponsor: Akeso
- Enrolled: 265

## Sources

- ClinicalTrials.gov NCT07623356: https://clinicaltrials.gov/study/NCT07623356

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct07623356.json